雅培
ABT
104.89
+0.21
+0.20%
雅培
US · ABT
#113 按市值排名
上市于 1970
104.89
+0.21
+0.20%
实时 - 追踪5344个代码 - 心跳于535秒前
· 2026-10-16 20:02
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了9家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 81.08% -0.02pp
- 机构数量
- 3,372 -9
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流入——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund65.44%
Public Company4.61%
Hedge Fund3.35%
Private Company2.97%
Government Pension Fund1.83%
Sovereign Wealth Fund1.41%
Family Office/Trust0.57%
Individual/Insider0.50%
Insurance Company0.31%
Other19.02%
主要股东 截至 2026-06-30
BlackRock
8.82% · 152.56M 股
Vanguard Capital Management, LLC
7.14% · 123.53M 股
State Street Global Advisors
4.68% · 80.93M 股
Capital Research
4.21% · 72.87M 股
Charles Schwab Investment Management
3.45% · 59.70M 股
Other
71.71%
Vanguard Portfolio Management, LLC
2.83% · 49.02M 股
Geode Capital Management, LLC
2.27% · 39.22M 股
Norges Bank Investment Management
1.35% · 23.35M 股
T. Rowe Price Group, Inc.
1.33% · 23.06M 股
UBS Asset Management
1.17% · 20.19M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 36次买入 · 12次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Daniel Starks | Independent Director | 0.39% |
| Robert Ford | Chairperson & CEO | 0.03% |
| Robert Funck | Officer | 0.02% |
| Hubert Allen | General Counsel | 0.01% |
| Daniel Salvadori | Executive VP and Group President of Established Pharmaceuticals & Nutritional Products | 0.01% |
| Mary Moreland | Officer | 0.01% |
| Lisa Earnhardt | Executive Vice President of Medical Devices | 0.01% |
| Philip Boudreau | CFO & Senior VP of Finance | 0.00% |
| Kevin Conroy | Director | 0.00% |
| Andrea Wainer | Executive Vice President of Rapid & Molecular Diagnostics | 0.00% |
| Christopher Scoggins | Former Senior Vice President of Rapid Diagnostics | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-29 | John Stratton | Independent Director | Other Derivative Acquisition | +397 | -- |
| 2026-09-29 | Kevin Conroy | Director | Other Derivative Acquisition | +318 | -- |
| 2026-09-29 | Michael Roman | Independent Director | Other Derivative Acquisition | +381 | -- |
| 2026-09-29 | Patricia Gonzalez | Independent Director | Other Derivative Acquisition | +333 | -- |
| 2026-09-29 | Nita Ahuja | Director | Other Derivative Acquisition | +318 | -- |
| 2026-09-22 | Kevin Conroy | Director | Sale to Issuer | -52,507 | $103.99 |
| 2026-09-01 | John McCoy | VP, Controller & Treasurer | Open Market Disposition | -27 | $109.54 |
| 2026-08-31 | John McCoy | VP, Controller & Treasurer | Sale to Issuer | -52 | $110.36 |
| 2026-08-31 | Philip Boudreau | CFO & Senior VP of Finance | Sale to Issuer | -388 | $110.36 |
| 2026-08-24 | Robert Ford | Chairperson & CEO | Derivative Exercise and Sale | -398,832 | $44.40–116.19 |
| 2026-08-11 | Louis Morrone | Executive Vice President of Core Diagnostics | Disposition Under Employee Benef | -12 | $107.99 |
| 2026-08-10 | Louis Morrone | Executive Vice President of Core Diagnostics | Open Market Disposition | -5,850 | $109.83 |
| 2026-06-29 | John Stratton | Independent Director | Other Derivative Acquisition | +432 | -- |
| 2026-06-29 | Kevin Conroy | Director | Other Derivative Acquisition | +231 | -- |
| 2026-06-29 | Michael Roman | Independent Director | Other Derivative Acquisition | +416 | -- |
| 2026-06-29 | Patricia Gonzalez | Independent Director | Other Derivative Acquisition | +363 | -- |
| 2026-06-29 | Louis Morrone | Executive Vice President of Core Diagnostics | Sale to Issuer | -269 | $92.71 |
| 2026-06-29 | Nita Ahuja | Director | Other Derivative Acquisition | +347 | -- |
| 2026-06-26 | Elizabeth Cushman | Senior Vice President of Legal | Sale to Issuer | -560 | $94.12 |
| 2026-05-14 | Robert Alpern | Independent Director | Intent to Sell (Form 144) | -7,587 | $85.25 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:02:12 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
雅培 讨论区 0 条评论